Evidence map›Paper›PMID 31369144›Full record

ArticleActa psychiatrica Scandinavica2019

Repetitive enhancement of serum BDNF subsequent to continuation ECT.

T Vanicek, G S Kranz, B Vyssoki, A Komorowski, G Fugger, A Höflich, Z Micskei, S Milovic, R Lanzenberger, A Eckert and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Acta psychiatrica Scandinavica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

T VanicekDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-5116-9899
G S KranzDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
B VyssokiDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-1195-630X
A KomorowskiDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
G FuggerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
A HöflichDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Z MicskeiDepartments of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.
S MilovicDepartments of Anesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.
R LanzenbergerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-4641-9539
A EckertNeurobiology Laboratory for Brain Aging and Mental Health, Transfaculty Research Platform Molecular & Cognitive Neuroscience (MCN), University of Basel, Basel, Switzerland.ORCID 0000-0002-9341-3669
S KasperDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-8278-191X
R FreyDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Medical University of Vienna · ATHong Kong Polytechnic University · HKUniversity of Basel · CH

Funding

Austrian Science Fund FWF P 23021
6 · The paper itself

Abstract

introductionContinuation electroconvulsive therapy (c-ECT) is highly effective for the prevention of depressive symptom relapse. There is a lack of understanding, about how c-ECT works in humans, particularly with regard to its effects on brain derived neurotrophic factor (BDNF) concentrations. Here, we aimed to close a gap in the literature by evaluating BDNF levels in patients receiving c-ECT.

methodsWe included 13 patients with either unipolar or bipolar depression (mean age ± SD: 55.5 ± 17.1; f/m: 10/3; unipolar/bipolar: 10/3) who received between one and four c-ECT (average per patient: 2.8). Serum BDNF (sBDNF) levels were assessed before and after each c-ECT sessions. Clinical assessments were also administered both before and after treatment.

resultsOur analysis revealed a significant increase in sBDNF after each treatment (c-ECT 1-3: P < 0.001, c-ECT 4: P = 0.018). The application of multiple c-ECT treatments was not, however, associated with further sBDNF enhancements. Psychometric scores were not significantly altered following c-ECT. DISCUSSION: An increase in sBDNF concentrations subsequent to c-ECT parallel data from the animal literature, which has linked regularly applied electrical stimulation to neuroplastic processes. This finding suggests a relationship between ECT-induced sBDNF concentrations and (sustained) remission status, considering a stable clinical condition across c-ECT.

Indexed as

Electroconvulsive TherapyAdultAgedBipolar DisorderBrain-Derived Neurotrophic FactorDepressive DisorderFemaleHumansMaleMiddle AgedSecondary PreventionYoung AdultBDNF protein, humanBrain-Derived Neurotrophic Factorbrain-derived neurotrophic factorcontinuation electroconvulsive therapydepressionunipolar and bipolar affective disorder

Identifiers

PMID31369144
PMCPMC6856812
OpenAlexW2965923505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.